Nicotinamide adenine dinucleotide (NAD+) delivered via the intranasal route is a subject of growing interest in neurochemical and metabolic research. This delivery mechanism is studied primarily for its potential to bypass traditional digestive degradation, allowing researchers to evaluate direct central nervous system (CNS) availability and mucosal absorption rates.

Current laboratory applications focus on its role in mitochondrial homeostasis, neuroprotection, and cellular repair within concentrated tissue environments. By utilizing an intranasal application protocol in animal models or isolated tissue studies, researchers can observe how NAD+ interacts with poly(ADP-ribose) polymerases (PARPs) and sirtuins (SIRTs) when administered directly to mucosal membranes, providing distinct pharmacokinetic data compared to subcutaneous or intravenous applications.